Helicobacter pylori Eradication: A Randomized Prospective Study of Triple Therapy Versus Triple Therapy Plus Lactoferrin and Probiotics

Bortoli, Nicola de; Leonardi, Giulia C.; Ciancia, Eugenio; Merlo, Andrea; Bellini, Massimo; Costa, Francesco; Mumolo, M.G.; Ricchiuti, Angelo; Cristiani, Fabrizio; Santi, Stefano; Rossi, Mauro; Marchi, Santino

doi:10.1111/j.1572-0241.2007.01085.x

Cited by 117 publications

(83 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The occurrence of side-effects can reduce the compliance with treatment regimens and lead to the development of bacterial resistance. 9 In the EAC 7 group 10 patients (16.7%) were lost to follow-up whereas in the EAC 14 group 12 (20%) were lost to follow-up, but …”

Section: Resultsmentioning

confidence: 99%

Helicobacter pylori eradication: A randomised comparative trial of 7-day versus 14-day triple therapy

et al. 2012

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Helicobacter pylori eradication: A randomised comparative trial of 7-day versus 14-day triple therapy

et al. 2012

View full text Add to dashboard Cite

“…In fact, it was reported that Lactoferrin, the precursor of Lfcin B, has a dramatic inhibitory effect on certain pathogens while probiotics such as Bifidobacterium and Lactobacillus were not affected by Lactoferrin (60). Furthermore, the combination of Lactoferrin with probiotics has been confirmed to have enhanced antibacterial effect in the clinical trials designed to overcome the infections caused by Helicobacter pylori (61). However, the reason that LfcinB inhibited pathogens but not probiotics in animal model experiments and clinical trials remains unclear (62,63).…”

Section: Fig 5 the Kinase Assaysmentioning

confidence: 95%

Lactoferricin B Inhibits the Phosphorylation of the Two-Component System Response Regulators BasR and CreB

Sung

Chen

2012

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Natural antimicrobial peptides provide fundamental protection for multicellular organisms from microbes, such as Lactoferricin B (Lfcin B). Many studies have shown that Lfcin B penetrates the cell membrane and has intracellular activities. To elucidate the intracellular behavior of Lfcin B, we first used Escherichia coli K12 proteome chips to identify the intracellular targets of Lfcin B. The results showed that Lfcin B binds to two response regulators, BasR and CreB, of the two-component system. For further analysis, we conducted several in vitro and in vivo experiments and utilized bioinformatics methods. The electrophoretic mobility shift assays and kinase assays indicate that Lfcin B inhibits the phosphorylation of the response regulators (BasR and CreB) and their cognate sensor kinases (BasS and CreC). Antibacterial assays showed that Lfcin B reduced E. coli's tolerance to environmental stimuli, such as excessive ferric ions and minimal medium conditions. This is the first study to show that an antimicrobial peptide inhibits the growth of bacteria by influencing

show abstract

“…Two recent metaanalyses suggest a modest effect 70,71 . Studies are needed to identify which strains to use and what is the best delivery system to achieve reliable results.…”

Section: Thinking Outside the Box: The Use Of Treatment Enhancersmentioning

confidence: 99%

New concepts of resistance in the treatment of Helicobacter pylori infections

Graham

Shiotani

2008

Nat Rev Gastroenterol Hepatol

312

368

View full text Add to dashboard Cite

SummaryThe prevalence of antimicrobial resistance is now such that all patients should be considered as having resistant infections. Ideally therapy is based on pretreatment susceptibility testing. Empiric therapies should assume antimicrobial resistance and use higher doses for 14 days. Acceptable results are 90-94% cure intention to treat (Grade B) or greater. Clarithromycin-containing triple therapies now typically produce ≤80% cure ITT (Grade F) and are no longer acceptable empiric therapy. Current initial therapy options are between sequential therapy, concomitant therapy, and bismuth containing quadruple therapy. Sequential therapy has the potential to be improved to ≥95% cure ITT (Grade A) by continuing the amoxicillin through the second and/or by increasing the duration. Better appreciation of the role of acidity in phenotypic resistance has resulted in high cure rates with high dose PPI plus amoxicillin dual therapy; additional studies to devise better dual-based multidrug regimes are still needed. Antimicrobial choices following treatment failure is best approached by susceptibility testing. If not available, we recommended a bismuth containing quadruple therapy substituting a new drug for metronidazole/tinidazole and/or clarithromycin if they have been used previously. The alternate would be to use a 14 day high dose PPI, amoxicillin-based triple therapy with rifabutin, a fluoroquinolone, or furazolidone. KeywordsHelicobacter pylori; therapy; resistance; antibiotics; anti-secretory drugs; phenotypic drug resistance; cytochrome P450 "To read without reflecting is like eating without digesting". -86-462-1111-86-462- , FAX 81-86-464-1195 Review criteria: We searched the relevant papers by using computer-assisted bibliographic searches of PubMed through November 30, 2007 using combinations of the following terms: H. pylori combined with resistance, therapy, eradication, second, triple, quadruple, sequential, or rescue. We also reviewed the recent literature on pharmacokinetics and pharmacodynamics in relation to the drugs used in H. pylori therapy and the relation to host cytochrome P450 genotypes to treatment outcome. We did not perform meta-analyses. We reviewed only articles published in English.

show abstract

Helicobacter pylori Eradication: A Randomized Prospective Study of Triple Therapy Versus Triple Therapy Plus Lactoferrin and Probiotics

Abstract: The results of our study suggest that the addition of bLf and Pbs could improve the standard eradication therapy for H. pylori infection--bLf serving to increase the eradication rate and Pbs to reduce the side effects of antibiotic therapy.

Cited by 117 publications

References 37 publications

Helicobacter pylori eradication: A randomised comparative trial of 7-day versus 14-day triple therapy

Helicobacter pylori eradication: A randomised comparative trial of 7-day versus 14-day triple therapy

Lactoferricin B Inhibits the Phosphorylation of the Two-Component System Response Regulators BasR and CreB

New concepts of resistance in the treatment of Helicobacter pylori infections

Contact Info

Product

Resources

About